Pathobiology of HBV mutants and clinical impact for treatment monitoring

References

• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology45(2), 507–539 (2007).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int.25(3), 472–489 (2005).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B. J. Hepatol.50(2), 227–242 (2009).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology45(4), 1056–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology46, 254–265 (2007).
   PubMed Web of Science ®Google Scholar
• Si Ahmed SN, Tavan D, Pichoud C et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology32, 1078–1088 (2000).
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med.357, 2576–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Wei LJ, Xu D, Brecker B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside naive patients. Clin. Drug. Invest.27(1), 35–39 (2007).
   PubMed Web of Science ®Google Scholar
• Leung N, Peng CY, Sollano J et al. Entecavir results in greater HBV DNA reduction versus adefovir in chronically infected HBeAg+ antiviral naive adults: 48 week results (EARLY study). Presented at: 42nd Annual Meeting of the European Association for the Study of the Liver 2007. Barcelona, Spain, 11–15 April 2007.
   Google Scholar
• Zoulim F. New nucleic acid diagnostic tests in viral hepatitis. Semin. Liver Dis.26(4), 309–317 (2006).
   PubMed Web of Science ®Google Scholar
• Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin. Liver Dis.26(2), 171–180 (2006).
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol.39(6), 1085–1089 (2003).
   PubMed Web of Science ®Google Scholar
• Brunelle MN, Jacquard AC, Pichoud C et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology41(6), 1391–1398 (2005).
   PubMed Web of Science ®Google Scholar
• Villet S, Pichoud C, Villeneuve JP et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology131(4), 1253–1261 (2006).
   PubMed Web of Science ®Google Scholar
• Yang H, Qi X, Sabogal A et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir. Ther.10(5), 625–633 (2005).
   PubMed Web of Science ®Google Scholar
• Brunelle MN, Lucifora J, Neyts J et al.In vitro activity of 2, 4-diamino-6[2-(phosphonome-thoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus (HBV) mutants. Antimicrob. Agents Chemother.51(6), 2240–2243 (2007).
   PubMed Web of Science ®Google Scholar
• Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antivir. Res.64(1), 1–15 (2004).
   PubMed Web of Science ®Google Scholar
• Ono SK, Kato N, Shiratori Y et al. The polymerase L 528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest.107, 449–455 (2001).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Dusheiko G, Hatzakis A et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology134, 405–415 (2008).
   PubMed Web of Science ®Google Scholar
• Solmone M, Vincenti D, Prosperi MC et al. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug resistant and drug naive patients and to detect minor variants in reverse transcriptase and hepatitis B s antigen. J. Virol.83(4), 1718–1726 (2009).
   PubMed Web of Science ®Google Scholar
• Zoulim F, Poynard T, Degos F et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J. Viral. Hepat.13(4), 278–288 (2006).
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology125(6), 1714–1722 (2003).
   PubMed Web of Science ®Google Scholar
• Lai CL, Dienstag J, Schiff e et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis.36(6), 687–696 (2003).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of Hbe-Ag-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology40(4), 883–891 (2004).
   PubMed Web of Science ®Google Scholar
• Hadziyannis S, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for Hbe-Ag-negative chronic hepatitis B for up to 5 years. Gastroenterology131(6), 1743–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lee Lim SG et al. Long term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology48(3), 750–758 (2008).
   PubMed Web of Science ®Google Scholar
• Zoulim F. Hepatitis B virus resistance to entecavir in nucleoside naive patients: does it exist? Hepatology44(6), 1404–1407 (2006).
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HbeAg-positive chronic hepatitis B. Gastroenteroloy130(7), 2039–2049 (2006).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N et al. 2 year globe trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology136(2), 486–495 (2009).
   PubMed Web of Science ®Google Scholar
• Yoo BC, Kim JH, Kim TH et al. Clevudine is highly efficacious in hepatitis B e antigene-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology46(4), 1041–1048 (2007).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z et al. Two year of adefovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBe Ag-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology48(4 Suppl.), A146 (2008).
   PubMed Web of Science ®Google Scholar
• Heathcote J, Gane E, deMan R et al. Two year of adefovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBe Ag-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology48(4 Suppl.), A158 (2008).
   Google Scholar
• Snow-Lampart A, Chapell B, Curtis M et al. Week 96- resistance surveillance for HBe Ag-positive and negative subjects with chronic hepatitis B randomized to receive tenofovir DF 300 mg qd. chronic Hepatology48(4 Suppl.), A977 (2008).
   Google Scholar
• Sheldon J, Camino N, Rodes B et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther.10(6), 727–734 (2005).
   PubMed Web of Science ®Google Scholar
• Delaney WE, Ray AS, Yang H et al. Intracellular metabolism and In vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother.50(7), 2471–2477 (2006).
   PubMed Web of Science ®Google Scholar
• Van Bommel F, Zollner B, Sarrazin c et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology44(2), 318–325 (2006).
   PubMed Web of Science ®Google Scholar
• Van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology40(6), 1421–1425 (2004).
   PubMed Web of Science ®Google Scholar
• Lacombe K, Gozlan J, Boelle PY et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS19(9), 907–915 (2005).
   PubMed Web of Science ®Google Scholar
• Dore GJ, Cooper DA, Pozniak AL et al. Efficacy of tenofovir disoproxil fumarate in anti-retroviral therapy-naive and-experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis.189(7), 1185–1192 (2004).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Fleury H, Trimoulet P et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology43(3), 548–555 (2006).
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Palmer P, Scieux C et al. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients co infected with HIV-1 and wild-type hepatitis B virus. Clin. Infect. Dis.39(7), 1062–1064 (2004).
   PubMed Web of Science ®Google Scholar
• Carrouée-Durantel S, Durantel D, Werle-Lapostolle B et al. Sub optimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside naive patients is not due to pre-existing drug resistant mutants. Antivi. Ther.13(3), 381–388 (2008).
   PubMed Web of Science ®Google Scholar
• Langley DR, Walsh AW, Baldick CJ et al. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol.81(8), 3992–4001 (2007).
   PubMed Web of Science ®Google Scholar
• Delmas J, Schorr O, Jamard C et al. Inhibitory effect of adefovir on viral synthesis and covalently circular DNA formation in duck hepatitis B virus infected hepatocytes in vivo and In vitro. Antimicrob. Agents Chemother.46(2), 425–433 (2000).
   Web of Science ®Google Scholar
• Yuen MF, Sablon E, Hui CK et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology34(4), 785–791 (2001).
   PubMed Web of Science ®Google Scholar
• Webster GJ, Reignat S, Brown D et al. Longitudinal analysis of CD8+ T cells specicific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol.78(11), 5707–5719 (2004).
   PubMed Web of Science ®Google Scholar
• Gehring AJ, Sun D, Kennedy PT et al. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J. Virol.81(6), 2940–2949 (2007).
   PubMed Web of Science ®Google Scholar
• Gunther S, Fischer L, Pult I et al. Naturally occurring variants of hepatitis B virus. Adv. Virus Res.52, 125–137 (1999).
   Google Scholar
• Kirishima T, Okanoue T, Daimon Y et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J. Hepatol.37, 259–265 (2002).
   PubMed Web of Science ®Google Scholar
• Jardi R, Rodriguez-Frias F, Schaper M et al. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J. Viral. Hepat.14, 835–840 (2007).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother.51, 902–911 (2007).
   PubMed Web of Science ®Google Scholar
• Litwin S, Toll E, Jilbert AR, Mason WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J. Clin. Virol.34(Suppl. 1), S96–S107 (2005).
   Google Scholar
• Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc. Natl Acad. Sci. USA101, 638–640 (2004).
   PubMed Web of Science ®Google Scholar
• Villet S, Billioud G, Pichoud Cet al.In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology136(1), 168–176 (2009).
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology44(6), 1656–1665 (2006).
   PubMed Web of Science ®Google Scholar
• Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology33(6), 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology124(1), 105–117 (2003).
   PubMed Web of Science ®Google Scholar
• Fung SK, Andreone P, Han SH et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol.43(6), 937–943 (2005).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351, 1521–1531 (2004).
   PubMed Web of Science ®Google Scholar
• Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transpl.14(Suppl. 2), S1–S7 (2008).
   Web of Science ®Google Scholar
• Lok A. How to diagnose and treat hepatitis B antiviral drug resistance in the liver transplant setting. Liver Transpl.14(Suppl. 2), S8–S14 (2008).
   Google Scholar
• Locarnini S. The haunting spectre of viral resistance in HBV. Presented at: American Association for the Study of Liver Diseases. San Francisco, CA, USA 31 October–1 November 2008.
   Google Scholar
• Torresi J, Earnest-Silveira L, Deliyannis G et al. Reduced antigenecity of the hepatitis B virus HBsAg arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology293(2), 305–313 (2002).
   PubMed Web of Science ®Google Scholar
• Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with lamivudine-resistant hepatitis B virus. AIDS16(1), 131–133 (2002).
   PubMed Web of Science ®Google Scholar
• Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin. Liver Dis.11, 869–892 (2007).
   PubMedGoogle Scholar
• Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology126, 91–101 (2004).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J. Viral. Hepat.13, 250–255 (2006).
   PubMed Web of Science ®Google Scholar
• Lampertico P, Marzano A, Levrero M et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HbeAg-negative chronic hepatitis B. Hepatology44(Suppl. 1), 639A (2006) (Abstract LB5).
   Web of Science ®Google Scholar
• Fung J, Lai CL, Yuen JC et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir. Ther.12, 41–46 (2007).
   PubMed Web of Science ®Google Scholar
• Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HbeAg-negative chronic hepatitis B. Hepatology45, 307–313 (2007).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol.5, 890–897 (2007).
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgetmann M, Dandri M et al. Peginterferon α-2b plus adefovir induce strong cccDNA declineand HBs Ag reduction in patients with chronic hepatitis B. Hepatology44(3), 675–684 (2006).
   PubMed Web of Science ®Google Scholar